Abstract 1883: A novel T cell engager targeting BCMA and GPRC5D showed promising preclinical activity with low toxic risk for multiple myeloma treatment
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1883
Abstract: Background: Multiple myeloma (MM) has become the second most hematological malignance. The patients are rarely cured and experience the recurrence or resistance. There is still an urgent need to develop potential therapeutic agents with better… read more here.
Keywords: cell; gprc5d; bcma; scr 8572 ... See more keywords
Abstract 5206: A novel mouse model for preclinical efficacy evaluation of anti-CD3/GPRC5D bispecific antibodies
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5206
Abstract: The FDA has granted Breakthrough Therapy Designation (BTD) for talquetamab, which targets both GPRC5D on multiple myeloma cells and CD3 on T-cells, for treating adult patients with relapsed or refractory multiple myeloma. Results showed that… read more here.
Keywords: anti cd3; gprc5d bispecific; gprc5d; cd3 gprc5d ... See more keywords